Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.79−0.33 (-3.26%)

Close on Nov 12, 2026Market cap $103.30MP/E –Yield –

Biodesix profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Biodesix's profit margin for the twelve months ending Sep 30, 2026 was -25.7%. For fiscal 2025 it was -39.8%, against -60.2% the year before. The highest annual figure on record is -39.8% in fiscal 2025.

Annual profit margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-39.8%	+20.3
FY2024	Dec 31, 2024	-60.2%	+46.0
FY2023	Dec 31, 2023	-106.2%	+65.0
FY2022	Dec 31, 2022	-171.3%	−92.1
FY2021	Dec 31, 2021	-79.2%	+64.5
FY2020	Dec 31, 2020	-143.7%	−18.5
FY2019	Dec 31, 2019	-125.1%	–

Quarterly profit margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-33.4%	+6.6
Q2 FY2026	Jun 30, 2026	-27.1%	+30.2
Q1 FY2026	Mar 31, 2026	-30.5%	+31.3
Q4 FY2025	Dec 31, 2025	-13.8%	+26.5
Q3 FY2025	Sep 30, 2025	-40.0%	+16.5
Q2 FY2025	Jun 30, 2025	-57.3%	+3.0
Q1 FY2025	Mar 31, 2025	-61.8%	+30.1
Q4 FY2024	Dec 31, 2024	-40.4%	+21.9
Q3 FY2024	Sep 30, 2024	-56.5%	+24.6
Q2 FY2024	Jun 30, 2024	-60.3%	+52.2
Q1 FY2024	Mar 31, 2024	-91.9%	+114.6
Q4 FY2023	Dec 31, 2023	-62.3%	+149.4
Q3 FY2023	Sep 30, 2023	-81.2%	+42.2
Q2 FY2023	Jun 30, 2023	-112.5%	+32.0
Q1 FY2023	Mar 31, 2023	-206.5%	+31.5
Q4 FY2022	Dec 31, 2022	-211.7%	−27.8
Q3 FY2022	Sep 30, 2022	-123.3%	+53.0
Q2 FY2022	Jun 30, 2022	-144.5%	−48.6
Q1 FY2022	Mar 31, 2022	-238.0%	−213.9
Q4 FY2021	Dec 31, 2021	-183.9%	−40.9
Q3 FY2021	Sep 30, 2021	-176.3%	−80.1
Q2 FY2021	Jun 30, 2021	-95.9%	+99.1
Q1 FY2021	Mar 31, 2021	-24.1%	+166.3
Q4 FY2020	Dec 31, 2020	-142.9%	−64.0
Q3 FY2020	Sep 30, 2020	-96.2%	+147.3
Q2 FY2020	Jun 30, 2020	-195.0%	–
Q1 FY2020	Mar 31, 2020	-190.5%	–
Q4 FY2019	Dec 31, 2019	-78.9%	–
Q3 FY2019	Sep 30, 2019	-243.6%	–